Posted by Michael Wonder on 11 Jan 2022
SIGA Technologies receives approval from the European Medicines Agency for tecovirimat
10 January 2021 - Broader indication to include smallpox, monkeypox, cowpox and vaccinia complications.
SIGA Technologies today announced that the EMA approved SIGA’s marketing authorisation application for oral tecovirimat, the same formulation that was approved by the U.S. FDA in July 2018 under the brand name Tpoxx.
